MDM4rs4245739 gene polymorphism and breast cancer susceptibility:A meta-analysis

doi:10.3969/j.issn.1004-583X.2022.11.003

Abstract

Abstract:

Objective To explore associations between MDM4rs4245739 gene polymorphism and breast cancer susceptibility. Methods The papers related to polymorphisms of MDM4rs4245739 and breast cancer susceptibility were searched in PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure and Wanfang electronic database. Odds ratios (ORs) and 95% confidence intervals (CIs) were adopted to assess the strength of associations. Publication bias was evaluated by Begg's funnel plot and Egger's linear regression test. Results A total of 6 studies involving 9 814 breast cancer patients and 45 202 healthy individuals were included in the present study. MDM4rs4245739 in the allelic (C vs A: OR=0.84, 95%CI: 0.67-1.05, P =0.118), dominant (AC+CC vs AA: $O R$ =0.86, 95% CI: 0.67-1.11, P =0.245), recessive (AC+AA vs CC: OR=0.90, 95%CI: 0.61-1.32, P =0.585), heterozygous (AC vs AA: OR =0.88, 95%CI: 0.69-1.12, P=0.305), homozygous (CC vs AA: OR =0.90, 95% CI: 0.59-1.39, $P$ =0.649) genetic models show no association with the susceptibility to breast cancer. Moreover, GEPIA data confirmed that the expression level of MDM4 was not associated with the tumor staging and prognosis of breast cancer. Conclusion Neither MDM4rs4245739 gene polymorphism nor MDM4 expression level is associated with the susceptibility and prognosis in breast cancer patients.

Key words: breast cancer, murine double minute 4, susceptibility, gene polymorphism, meta analysis

CLC Number:

R604

Jiang Yan, Li Jiayang, Wu Hongyu, Chen Baolin, Cheng Xiaoming, Lyu Junyuan. MDM4rs4245739 gene polymorphism and breast cancer susceptibility:A meta-analysis[J]. Clinical Focus, 2022, 37(11): 977-984.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.11.003

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I11/977

Figures/Tables 12

第一作者	年份	地区	种族	病例/对照数	病例组			对照组			SOC	HWE	NOS
第一作者	年份	地区	种族	病例/对照数	AA	AC	CC	AA	AC	CC	SOC	HWE	NOS
Liu et al^[7]	2013	中国	非高加索人	800/800	733	67	0	686	111	3	PB	0.505	6
Liu et al^[7]	2013	中国	非高加索人	300/600	278	22	0	501	96	3	PB	0.483	6
Hashemi et al^[8]	2018	伊朗	非高加索人	265/221	175	83	7	142	70	9	HB	0.919	5
Montserrat et al^[10]	2013	混合	高加索人	6 512/41 451	3 318	2 637	557	22 825	15 798	2 828	Mixed	0.183	5
Gansmo et al^[25]	2015	挪威	高加索人	1 717/1 870	966	643	108	1 021	703	146	PB	0.106	6
Pedram et al^[26]	2016	伊朗	非高加索人	220/260	123	87	10	165	81	14	HB	0.335	6

分组	数量	C vs A		AC+CC vs AA		AC+AA vs CC		AC vs AA		CC vs AA
分组	数量	$O R$ (95% $C I$ )	$P$	$O R$ (95% $C I$ )	$P$	$O R$ (95% $C I$ )	$P$	$O R$ (95% $C I$ )	$P$	$O R$ (95% $C I$ )	$P$
种族
非高加索人	4	0.70(0.46-1.06)^*	0.093	0.74(0.44-1.22)^*	0.236	0.67(0.36-1.24)^#	0.200	0.76(0.45-1.28)^*	0.302	0.71(0.38-1.32)^#	0.279
高加索人	2	1.04(0.83-1.30)^*	0.753	1.06(0.84-1.33)^*	0.639	1.02(0.64-1.63)^*	0.923	1.06(0.90-1.26)^*	0.478	1.04(0.61-1.79)^*	0.876
地区
亚洲	4	0.70(0.46-1.06)^*	0.093	0.74(0.44-1.22)^*	0.236	0.67(0.36-1.24)^#	0.200	0.76(0.45-1.28)^*	0.302	0.71(0.38-1.32)^#	0.279
欧洲	1	0.92(0.83-1.02)	0.116	0.93(0.82-1.06)	0.292	0.79(0.61-1.03)	0.080	0.96(0.84-1.11)	0.590	0.78(0.60-1.02)	0.068
混合	1	1.16(1.11-1.21)	0.000	1.18(1.12-1.24)	0.000	1.28(1.16-1.41)	0.000	1.15(1.09-1.21)	0.000	1.36(1.23-1.49)	0.000
样本量
>1 000	2	1.04(0.83-1.30)^*	0.753	1.06(0.84-1.33)^*	0.639	1.02(0.64-1.63)^*	0.923	1.06(0.90-1.26)^*	0.478	1.04(0.61-1.79)^*	0.876
<1 000	4	0.70(0.46-1.06)^*	0.093	0.74(0.44-1.22)^*	0.236	0.67(0.36-1.24)^#	0.200	0.76(0.45-1.28)^*	0.302	0.71(0.38-1.32)^#	0.279
基因分型检测方法
PCR-RFLP	4	0.70(0.46-1.06)^*	0.093	0.74(0.44-1.22)^*	0.236	0.67(0.36-1.24)^#	0.200	0.76(0.45-1.28)^*	0.302	0.71(0.38-1.32)^#	0.279
其他	2	1.04(0.83-1.30)^*	0.753	1.06(0.84-1.33)^*	0.639	1.02(0.64-1.24)^*	0.923	1.06(0.90-1.26)^*	0.478	1.04(0.61-1.79)^*	0.876
健康对照者来源
PB	3	0.62(0.38-1.01)^*	0.054	0.61(0.37-1.02)^*	0.060	0.78(0.60-1.01)^#	0.054	0.63(0.38-1.05)^*	0.079	0.77(0.59-0.99)^#	0.044
HB	2	1.00(0.80-1.25)^#	0.976	1.13(0.77-1.66)^*	0.542	0.75(0.40-1.42)^#	0.378	1.18(0.79-1.75)^*	0.415	0.81(0.42-1.54)^#	0.518
混合	1	1.16(1.11-1.21)	0.000	1.18(1.12-1.24)	0.000	1.28(1.16-1.41)	0.000	1.15(1.09-1.21)	0.000	1.35(1.23-1.49)	0.000
总共	6	0.84(0.67-1.05)^*	0.118	0.86(0.67-1.11)^*	0.245	0.90(0.61-1.32)^*	0.585	0.88(0.69-1.12)^*	0.305	0.90(0.59-1.40)^*	0.649

分组	数量	C vs A		AC+CC vs AA		AC+AA vs CC		AC vs AA		CC vs AA
分组	数量	$O R$ (95% $C I$ )	$P$	$O R$ (95% $C I$ )	$P$	$O R$ (95% $C I$ )	$P$	$O R$ (95% $C I$ )	$P$	$O R$ (95% $C I$ )	$P$
种族
非高加索人	4	0.70(0.46-1.06)^*	0.093	0.74(0.44-1.22)^*	0.236	0.67(0.36-1.24)^#	0.200	0.76(0.45-1.28)^*	0.302	0.71(0.38-1.32)^#	0.279
高加索人	2	1.04(0.83-1.30)^*	0.753	1.06(0.84-1.33)^*	0.639	1.02(0.64-1.63)^*	0.923	1.06(0.90-1.26)^*	0.478	1.04(0.61-1.79)^*	0.876
地区
亚洲	4	0.70(0.46-1.06)^*	0.093	0.74(0.44-1.22)^*	0.236	0.67(0.36-1.24)^#	0.200	0.76(0.45-1.28)^*	0.302	0.71(0.38-1.32)^#	0.279
欧洲	1	0.92(0.83-1.02)	0.116	0.93(0.82-1.06)	0.292	0.79(0.61-1.03)	0.080	0.96(0.84-1.11)	0.590	0.78(0.60-1.02)	0.068
混合	1	1.16(1.11-1.21)	0.000	1.18(1.12-1.24)	0.000	1.28(1.16-1.41)	0.000	1.15(1.09-1.21)	0.000	1.36(1.23-1.49)	0.000
样本量
>1 000	2	1.04(0.83-1.30)^*	0.753	1.06(0.84-1.33)^*	0.639	1.02(0.64-1.63)^*	0.923	1.06(0.90-1.26)^*	0.478	1.04(0.61-1.79)^*	0.876
<1 000	4	0.70(0.46-1.06)^*	0.093	0.74(0.44-1.22)^*	0.236	0.67(0.36-1.24)^#	0.200	0.76(0.45-1.28)^*	0.302	0.71(0.38-1.32)^#	0.279
基因分型检测方法
PCR-RFLP	4	0.70(0.46-1.06)^*	0.093	0.74(0.44-1.22)^*	0.236	0.67(0.36-1.24)^#	0.200	0.76(0.45-1.28)^*	0.302	0.71(0.38-1.32)^#	0.279
其他	2	1.04(0.83-1.30)^*	0.753	1.06(0.84-1.33)^*	0.639	1.02(0.64-1.24)^*	0.923	1.06(0.90-1.26)^*	0.478	1.04(0.61-1.79)^*	0.876
健康对照者来源
PB	3	0.62(0.38-1.01)^*	0.054	0.61(0.37-1.02)^*	0.060	0.78(0.60-1.01)^#	0.054	0.63(0.38-1.05)^*	0.079	0.77(0.59-0.99)^#	0.044
HB	2	1.00(0.80-1.25)^#	0.976	1.13(0.77-1.66)^*	0.542	0.75(0.40-1.42)^#	0.378	1.18(0.79-1.75)^*	0.415	0.81(0.42-1.54)^#	0.518
混合	1	1.16(1.11-1.21)	0.000	1.18(1.12-1.24)	0.000	1.28(1.16-1.41)	0.000	1.15(1.09-1.21)	0.000	1.35(1.23-1.49)	0.000
总共	6	0.84(0.67-1.05)^*	0.118	0.86(0.67-1.11)^*	0.245	0.90(0.61-1.32)^*	0.585	0.88(0.69-1.12)^*	0.305	0.90(0.59-1.40)^*	0.649

协变量	N	C vs A	AC+CC vs AA	AC+AA vs CC	AC vs AA	CC vs AA
种族	2	0.201	0.341	0.244	0.388	0.301
地区	3	0.000	0.000	0.000	0.000	0.000
样本量	2	0.201	0.341	0.244	0.388	0.301
基因分型检测方法	2	0.201	0.341	0.244	0.388	0.301
健康对照者来源	3	0.000	0.000	0.000	0.000	0.000

References 27

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 71(3): 209-249. doi: 10.3322/caac.21660 URL
[2]	Lilyquist J, Ruddy KJ, Vachon CM, et al. Common genetic variation and breast cancer risk-past, present, and future[J]. Cancer Epidemiol Biomarkers Prev, 2018, 27(4): 380-394. doi: 10.1158/1055-9965.EPI-17-1144 URL
[3]	Rudolph A, Chang-Claude J, Schmidt MK. Gene-environment interaction and risk of breast cancer[J]. Br J Cancer, 2016, 114(4): 125-133. doi: 10.1038/bjc.2015.439 URL
[4]	Rahman N. Realizing the promise of cancer predisposition genes[J]. Nature, 2014, 505(7483): 302-308. doi: 10.1038/nature12981 URL
[5]	Haupt S, Vijayakumaran R, Miranda PJ, et al. The role of MDM2 and MDM4 in breast cancer development and prevention[J]. J Mol Cell Biol, 2017, 9(1):53-61. doi: 10.1093/jmcb/mjx007 pmid: 28096293
[6]	Stegeman S, Moya L, Selth LA, et al. A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer[J]. Endocr Relat Cancer, 2015, 22(2): 265-276. doi: 10.1530/ERC-15-0013 URL
[7]	Liu J, Tang X, Li M, et al. Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility[J]. Breast Cancer Res Treat, 2013, 140(1): 151-157. doi: 10.1007/s10549-013-2615-x URL
[8]	Hashemi M, Sanaei S, Hashemi SM, et al. Association of single nucleotide polymorphisms of the MDM4 gene with the susceptibility to breast cancer in a Southeast Iranian population sample[J]. Clin Breast Cancer, 2018, 18(5): e883-e891. doi: 10.1016/j.clbc.2018.01.003 URL
[9]	Wang YX, Yang Z, Chang XL, et al. Five MDM4 gene polymorphisms on cancer risk: An updated systematic review and meta-analysis[J]. Int J Biol Markers, 2021, 36(2): 17246008211033874.
[10]	Montserrat GC, Couch FJ, Lindstrom S, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci[J]. Nat Genet, 2013, 45(4): 392-398e2. doi: 10.1038/ng.2561 URL
[11]	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605. doi: 10.1007/s10654-010-9491-z pmid: 20652370
[12]	Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis[J]. Stat Med, 2002, 21(11): 1539-1558. doi: 10.1002/sim.1186 pmid: 12111919
[13]	Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis[J]. JAMA, 2006, 295(6): 676-680. doi: 10.1001/jama.295.6.676 pmid: 16467236
[14]	Jin X, Zhao W, Zheng M, et al. The role of MDM4 SNP34091 A>C polymorphism in cancer: A meta-analysis on 19, 328 patients and 51, 058 controls[J]. Int J Biol Markers, 2017, 32(1): e62-e67.
[15]	Wang MJ, Luo Y J, Shi ZY, et al. The associations between MDM4 gene polymorphisms and cancer risk[J]. Oncotarget, 2016, 7(34): 55611-55623. doi: 10.18632/oncotarget.10877 URL
[16]	Zhai Y, Dai Z, He H, et al. A PRISMA-compliant meta-analysis of MDM4 genetic variants and cancer susceptibility[J]. Oncotarget, 2016, 7(45): 73935-73944. doi: 10.18632/oncotarget.12558 pmid: 27738340
[17]	Song CG, Fu FM, Wu XY, et al. Correlation of polymorphism rsl563828 in MDM4 gene with breast cancer risk and onset age[J]. Chin J Surg, 2012, 50(1): 53-56.
[18]	Atwal GS, Kirchhoff T, Bond EE, et al. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene[J]. Proc Natl Acad Sci USA, 2009, 106(25): 10236-10241. doi: 10.1073/pnas.0901298106 URL
[19]	Bauer M, Kantelhardt EJ, Stiewe T, et al. Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients[J]. Oncotarget, 2019, 10(20): 1975-1992. doi: 10.18632/oncotarget.26768 URL
[20]	Vulsteke C, Lambrechts D, Dieudonne A, et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)[J]. Ann Oncol, 2013, 24(6): 1513-1525. doi: 10.1093/annonc/mdt008 pmid: 23396606
[21]	Kulkarni DA, Vazquez A, Haffty BG, et al. A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer[J]. Carcinogenesis, 2009, 30(11): 1910-1915. doi: 10.1093/carcin/bgp224 pmid: 19762336
[22]	Joseph V, Gaudet M, Devlin V, et al. Genetic variation of human MDM4 confers increased risk for breast cancer in the Ashkenazi Jewish population[J]. Curr Oncol, 2009, 16(5): 97.
[23]	Reincke S, Govbakh L, Wilhelm B, et al. Mutation analysis of the MDM4 gene in German breast cancer patients[J]. BMC cancer, 2008, 8: 52. doi: 10.1186/1471-2407-8-52 pmid: 18279506
[24]	Bartnykaite A, Savukaityte A, Ugenskiene R, et al. Associations of MDM2 and MDM4 polymorphisms with early-stage breast cancer[J]. J Clin Med, 2021, 10(4): 866. doi: 10.3390/jcm10040866 URL
[25]	Gansmo LB, Romundstad P, Birkeland E, et al. MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk[J]. Cancer med, 2015, 4(12): 1901-1907. doi: 10.1002/cam4.555 URL
[26]	Pedram N, Pouladi N, Feizi MA, et al. Analysis of the Association between MDM4 rs4245739 single nucleotide polymorphism and breast cancer susceptibility[J]. Clin lab, 2016, 62(7): 1303-1308. doi: 10.7754/Clin.Lab.2016.151128 pmid: 28164646
[27]	Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype classification, clinical use and future trends[J]. Am J Cancer Res, 2015, 5(10): 2929-2943. pmid: 26693050